Intermune Eyes Settlement Over Off-Label Marketing

Law360, New York (July 28, 2006, 12:00 AM EDT) -- Biotechnology company Intermune Inc. is preparing to pay as much as $30 million to settle allegations from federal prosecutors that it illegally promoted a drug for a use not approved by the U.S. Food and Drug Administration.

The U.S. Department of Justice began probing the Brisbane, Calif.-based company in 2004 after a former sales representative claimed she was fired for not taking part in off-label marketing—encouraging nonapproved uses of a drug.

The drug at the center of the controversy, Actimmune, currently has FDA approval for use...
To view the full article, register now.